Entrada Therapeutics files amended charter and bylaws in connection with IPO

Entrada Therapeutics, Inc.

Authorizes 150M shares of common stock and 10M shares of undesignated preferred stock.
Bylaws eliminate stockholder action by written consent, set procedures for proposals and nominations.
Changes previously disclosed in S-1; effective upon IPO consummation on November 2, 2021.

item 5.03 item 9.01

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-132980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.